文献速递泌尿生殖与妇科肿瘤放疗

前列腺直肠间隔物谁获益?III期试验二次分析

Who Benefits From a Prostate Rectal Spacer? Secondary Analysis of a Phase III Trial.
PubMed 文献 · Pract Radiat Oncol · 2020-01-21

即使>95%计划满足QUANTEC直肠剂量约束,水凝胶间隔物仍提供潜在有意义的获益。

要点

  • 间隔物使直肠V70相对降低78%,绝对降低在高V70者更大。
  • 在不同临床和剂量学变量组中,间隔物降低肠道QOL下降风险的相对获益无显著异质性。

核心结论

  • 在前列腺放疗中,水凝胶直肠间隔物降低肠道生活质量下降风险的相对获益在不同临床和剂量学变量间异质性很小。
  • 即使对于>95%满足QUANTEC直肠剂量约束的计划,水凝胶间隔物仍提供潜在有意义的获益。

研究设计与样本

  • 对SpaceOAR III期试验中222例患者的临床和剂量学数据进行二次分析。
  • 以直肠V70和QUANTEC直肠剂量目标作为临床获益和计划质量的替代指标。
  • 治疗后15和36个月评估平均肠道生活质量,并评估1倍(5分)或2倍(10分)最小重要差异变化的可能性。

主要发现

  • 前列腺体积与直肠V70无相关性(r=0.077)。
  • 最小前列腺(<40 mL)水凝胶前后直肠V70分别为13%和3%,最大前列腺(>80 mL)分别为12%和2%。
  • 直肠V70相对降低78%,不随间隔物前V70变化,但绝对降低在高V70者更大。
  • 所有间隔物计划满足5项QUANTEC直肠剂量约束,而92%对照计划满足所有约束。

关键数值与推荐

  • 前列腺体积与直肠V70无相关性(r=0.077)。
  • 最小前列腺(<40 mL)水凝胶前后直肠V70分别为13%和3%,最大前列腺(>80 mL)分别为12%和2%。
  • 直肠V70相对降低78%,不随间隔物前V70变化,但绝对降低在高V70者更大。
  • 所有间隔物计划满足5项QUANTEC直肠剂量约束,92%对照计划满足所有约束。

临床怎么用

  • 水凝胶直肠间隔物可考虑用于前列腺放疗患者,即使计划已满足QUANTEC直肠剂量约束,仍可能提供有意义的肠道生活质量获益。
  • 直肠V70可作为计划质量和临床获益的替代指标,用于评估间隔物使用的潜在获益。
  • 前列腺体积、年龄、BMI、既往手术、靶体积或计划质量不应作为排除间隔物使用的依据,因相对获益无显著异质性。

局限性

  • 本文为二次分析,未报告原始试验的主要终点以外的局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Previously a phase III trial of a hydrogel rectal spacer during prostate radiation therapy found decreased toxicity and a clinically significant improvement in bowel quality of life (QOL) at 3 years by the Expanded Prostate Cancer Index. We performed a secondary analysis to identify men less likely to benefit. METHODS AND MATERIALS: Clinical and dosimetric data for the 222 patients enrolled on the SpaceOAR phase III trial were analyzed. The volume of rectum treated to 70 Gy (V70) and the quantitative analysis of normal tissue effects in the clinic (QUANTEC) rectal dose goals were used as surrogates for clinical benefit and plan quality. Mean bowel QOL was assessed at 15 and 36 months posttreatment and the likelihood of 1× (5 points) or 2× (10 points) minimally important difference changes were assessed. RESULTS: Rectal V70 was correlated with physician scored toxicity (P = .033) and was used as a surrogate for plan quality. There was no correlation between prostate volume and rectal V70 (r = 0.077). Rectal V70 pre- and post-hydrogel was 13% and 3% for the smallest prostates (<40 mL) and 12% and 2% for the largest (>80 mL). The relative reduction in rectal V70 of 78% did not vary by prespacer V70, but the absolute reduction was greater for a higher V70. All spacer plans met the 5 QUANTEC rectal dose constraints, although 92% of control plans met all constraints. At 3 years, those not meeting all QUANTEC goals had a 15.0-point (standard deviation 15.1) decline, control patients meeting QUANTEC goals had a 4.0-point (9.5) decline, and spacer had >0.5 (7.6; P < .01). Previous surgery was not correlated with QOL (P = .8). Across prognostic groups, including age, body mass index, previous surgery, target volume, or quality of radiation plans, there was no statistically significant heterogeneity in the relative benefit of spacer in decreasing the risk of 1× or 2× the minimally important difference declines. CONCLUSIONS: There was little heterogeneity in the likelihood of spacer reducing the risk of declines in bowel QOL across clinical and dosimetric variables. Even for the >95% of plans meeting QUANTEC rectal criteria, hydrogel spacer provided potentially meaningful benefits.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Quinn TJ, Daignault-Newton S, Bosch W, et al. Who Benefits From a Prostate Rectal Spacer? Secondary Analysis of a Phase III Trial. Pract Radiat Oncol. 2020. PMID: 31978591. doi:10.1016/j.prro.2019.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。